Black Diamond Therapeutics/BDTX

$4.87

-8.97%
-
1D1W1MYTD1YMAX

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc. is a precision oncology medicine company. The Company is focused on the discovery and development of MasterKey therapies that target families of oncogenic mutations in clinically validated targets. Its technology platform, Mutation-Allostery-Pharmacology (MAP) platform is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. The Company’s lead product candidate, BDTX-1535 is a brain-penetrant inhibitor that targets a spectrum of epidermal growth factor receptor (EGFR) mutations, including allosteric and canonical mutations. Its second product candidate, BDTX-4933, is designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic B-Raf Proto-Oncogene (BRAF) Class I, II, III and active RAF dimers promoted by upstream oncogenic alterations, such as rat sarcoma virus (RAS) mutations, which has the potential to avoid paradoxical activation.
Ticker
BDTX
Sector
Tervishoid
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Mark Velleca
Employees
65
Headquarters
Cambridge, United States

BDTX Metrics

BasicAdvanced
$276.25M
Market cap
-
P/E ratio
-$2.13
EPS
2.64
Beta
-
Dividend rate

What the Analysts think about BDTX

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
113.55% upside
High $11.00
Low $10.00
$4.87
Current price
$10.40
Average price target

BDTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-23M
20.42%
Profit margin
0%
-

BDTX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.5%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.59
-$0.57
-$0.52
-$0.45
-
Expected
-$0.63
-$0.61
-$0.54
-$0.49
-$0.47
Surprise
-6%
-6.17%
-2.95%
-7.5%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Black Diamond Therapeutics stock

Buy or sell Black Diamond Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing